Trending

Synairgen

Synairgen starts dosing inhaled COVID-19 drug in phase 3 trial

Synairgen starts dosing inhaled COVID-19 drug in phase 3 trial

UK biotech Synairgen is pushing ahead with a phase 3 trial of SNG001 in hospitalised COVID-19 patients, after

X

Synairgen starts dosing inhaled COVID-19 drug in phase 3 trial

https://pharmaphorum.com/news/synairgen-starts-dosing-inhaled-covid-19-drug-in-phase-3-trial/

Synairgen’s inhaled drug cuts chances of COVID-19 progressing

Synairgen’s inhaled drug cuts chances of COVID-19 progressing

An inhaled drug developed by the UK firm Synairgen greatly reduces the chances of patients hospitalised with COVID-19 from progressing to more

X

Synairgen’s inhaled drug cuts chances of COVID-19 progressing

https://pharmaphorum.com/news/synairgens-inhaled-drug-cuts-chances-of-covid-19-progressing/

Synairgen doses first patients with COVID-19 drug

Synairgen doses first patients with COVID-19 drug

UK biotech Synairgen has started dosing patients in its phase 2 trial of SNG001, an inhaled formulation of

X

Synairgen doses first patients with COVID-19 drug

https://pharmaphorum.com/news/synairgen-doses-first-patients-with-covid-19-drug/

Duo of UK firms announce coronavirus therapy trials

Duo of UK firms announce coronavirus therapy trials

Two UK firms have announced plans to begin trials of therapies to tackle the coronavirus outbreak. Synairgen, based

X

Duo of UK firms announce coronavirus therapy trials

https://pharmaphorum.com/news/duo-of-uk-firms-announce-coronavirus-therapy-trials/

Synairgen under the weather after AZ halts asthma trial

Synairgen under the weather after AZ halts asthma trial

AZ assessing drug’s future following trial disappointment.

X

Synairgen under the weather after AZ halts asthma trial

https://pharmaphorum.com/news/synairgen-setback-az-halts-asthma-trial/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com